Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aspire Biopharma Holdings, Inc. - Warrant
(NQ:
ASBPW
)
0.0450
-0.0154 (-25.50%)
Streaming Delayed Price
Updated: 10:21 AM EDT, May 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aspire Biopharma Holdings, Inc. - Warrant
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
Today 8:00 EDT
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
April 29, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
April 14, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
April 11, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
April 09, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
March 20, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
March 13, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
March 03, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
February 25, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement
February 20, 2025
Via
ACCESS Newswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.